Stockholders' Equity (Tables)

9 Months Ended

Sep. 30, 2022

Stockholders' Equity Note [Abstract]

Stock-based Compensation Expense

The stock-based compensation related to our stock-based awards and employee stock purchase plan for the three and nine months ended September 30, 2022 and 2021 is as follows (in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
Cost of net revenues	$	1,651	$	1,451	$	4,779	$	4,175
Selling, general and administrative	25,293		22,229		76,509		67,131
Research and development	5,974		4,722		17,391		13,192
Total stock-based compensation	$	32,918	$	28,402	$	98,679	$	84,498

Summary Of Restricted Stock Units

A summary for the nine months ended September 30, 2022 is as follows:

	Number of Shares Underlying RSUs (in thousands)	Weighted Average Grant Date Fair Value		Weighted Average Remaining Contractual Term (in years)	Aggregate Intrinsic Value (in thousands)
Unvested as of December 31, 2021	492	$	369.17
Granted	239	478.94
Vested and released	(196)	334.10
Forfeited	(35)	433.42
Unvested as of September 30, 2022	500	$	430.73	1.4	$	103,619

Summary Of Market-performance Based Restricted Stock Units

The following table summarizes the MSU performance for the nine months ended September 30, 2022: 

	Number of Shares Underlying MSUs (in thousands)	Weighted Average Grant Date Fair Value		Weighted Average Remaining Contractual Term (in years)	Aggregate Intrinsic Value (in thousands)
Unvested as of December 31, 2021	174	$	551.57
Granted 1	101	607.96
Vested and released	(128)	396.10
Forfeited	(3)	744.39
Unvested as of September 30, 2022	144	$	725.73	1.2	$	29,838

Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions

The fair value of the option component of the 2010 Purchase Plan shares was estimated at the grant date using the Black-Scholes option pricing model with the following weighted average assumptions:

	Three Months Ended September 30,						Nine Months Ended September 30,
	2022			2021			2022			2021
Expected term (in years)	1.5			1.2			1.5			1.1
Expected volatility	52.3		%	51.1		%	50.2		%	52.7		%
Risk-free interest rate	2.9		%	0.1		%	1.8		%	0.1		%
Expected dividends	—			—			—			—
Weighted average fair value at grant date	$	112.84		$	257.89		$	159.44		$	246.84